Heart gene therapy trial pulled before it even started
NCT ID NCT01002495
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study was designed to test the safety of a gene therapy called VM202 in people with chronic refractory myocardial ischemia—severe chest pain that doesn't improve with standard treatments. The therapy would be injected directly into the heart via a catheter. However, the trial was withdrawn before enrolling any participants, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VM202 (gene therapy)
What this could lead to
If successful, VM202 could offer a new way to reduce chest pain and improve blood flow in patients with severe, untreatable heart ischemia.
What could go wrong
This trial was withdrawn before any patients enrolled, so no data exists. Gene therapies carry risks like inflammation or arrhythmia, and earlier-stage results are uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYOCARDIAL ISCHEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Minneapolis Heart Institute Foundation/ Abbott Northwestern Hospital
Minneapolis, Minnesota, 55407, United States
-
Northwestern Memorial Hospital
Chicago, Illinois, United States